Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hae Rim | - |
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Kang, Seonghee | - |
dc.contributor.author | Suh, Sang Jun | - |
dc.contributor.author | Kim, Seung Young | - |
dc.contributor.author | Hyun, Jong Jin | - |
dc.contributor.author | Koo, Ja Seol | - |
dc.contributor.author | Kim, Ji Hoon | - |
dc.contributor.author | Seo, Yeon Seok | - |
dc.contributor.author | Yeon, Jong Eun | - |
dc.contributor.author | Lee, Sang Woo | - |
dc.contributor.author | Byun, Kwan Soo | - |
dc.contributor.author | Um, Soon Ho | - |
dc.date.accessioned | 2021-09-04T18:28:58Z | - |
dc.date.available | 2021-09-04T18:28:58Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2015-03 | - |
dc.identifier.issn | 1478-3223 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/94181 | - |
dc.description.abstract | Background & AimsEntecavir (ETV) is effective in the treatment of chronic hepatitis B virus (HBV) infections, even in patients with underlying cirrhosis. However, there is little information on the effect of telbivudine (TBV) in chronic hepatitis B patients with cirrhosis.This study compared the antiviral efficacy of TBV and ETV in HBV-related cirrhosis. MethodsWe consecutively enrolled 151 treatment-naive patients with HBV-related cirrhosis who started antiviral therapy with TBV (n=61) or ETV (n=90). ResultsAfter 24months of treatment, per-protocol analysis showed similar virological response rates (HBV DNA <20IU/ml) in the TBV group (80.6%, 25/31) and in the ETV group (90.2%, 74/82) (P=0.167). However, intention-to-treat analysis showed lower virological response rates in the TBV group (41.7%, 25/60) than in the ETV group (83.1%, 74/89) (P=0.001). Mean reduction in HBV DNA levels was greater in the ETV group (-3.721.94 vs. -4.87 +/- 1.57 respectively, P=0.001). Serologic and biochemical response rates at month 24 did not differ significantly between the groups. Child-Turcotte-Pugh score was significantly improved after 24months compared to the pretreatment state without difference between the groups. During 24months of therapy, 15 patients (27.3%) showed antiviral resistance to TBV while no resistance (0%) was reported in the ETV group (P=0.001). ConclusionsCompared to ETV, TBV therapy shows lower efficacy in viral suppression and higher risk of antiviral resistance despite comparable effect on improvement of hepatic function for the treatment of HBV-related cirrhosis. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY-BLACKWELL | - |
dc.subject | POSITIVE CHRONIC HEPATITIS | - |
dc.subject | LAMIVUDINE | - |
dc.subject | INFECTION | - |
dc.subject | ADEFOVIR | - |
dc.subject | THERAPY | - |
dc.title | Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yim, Hyung Joon | - |
dc.contributor.affiliatedAuthor | Kim, Seung Young | - |
dc.contributor.affiliatedAuthor | Hyun, Jong Jin | - |
dc.contributor.affiliatedAuthor | Koo, Ja Seol | - |
dc.contributor.affiliatedAuthor | Kim, Ji Hoon | - |
dc.contributor.affiliatedAuthor | Seo, Yeon Seok | - |
dc.contributor.affiliatedAuthor | Yeon, Jong Eun | - |
dc.contributor.affiliatedAuthor | Lee, Sang Woo | - |
dc.contributor.affiliatedAuthor | Byun, Kwan Soo | - |
dc.contributor.affiliatedAuthor | Um, Soon Ho | - |
dc.identifier.doi | 10.1111/liv.12605 | - |
dc.identifier.scopusid | 2-s2.0-84940264044 | - |
dc.identifier.wosid | 000349781900019 | - |
dc.identifier.bibliographicCitation | LIVER INTERNATIONAL, v.35, no.3, pp.860 - 869 | - |
dc.relation.isPartOf | LIVER INTERNATIONAL | - |
dc.citation.title | LIVER INTERNATIONAL | - |
dc.citation.volume | 35 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 860 | - |
dc.citation.endPage | 869 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | POSITIVE CHRONIC HEPATITIS | - |
dc.subject.keywordPlus | LAMIVUDINE | - |
dc.subject.keywordPlus | INFECTION | - |
dc.subject.keywordPlus | ADEFOVIR | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | cirrhosis | - |
dc.subject.keywordAuthor | entecavir | - |
dc.subject.keywordAuthor | hepatitis B | - |
dc.subject.keywordAuthor | telbivudine | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.